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1. Introduction 
The role of liver biopsy (LB), the traditional gold standard for assessing liver disease, 
continues to evolve1-4. Fewer biopsies are being done for diagnosis as noninvasive tests such 
as new imaging techniques and accurate serological tests can now be done instead in many 
cases2-4. Most biopsies are currently performed for parenchymal disease not to make specific 
diagnosis but to assess the liver damage (the degree of inflammation, fibrosis) or the 
response to therapy5. In contrast to past when nearly all biopsies were done for diagnostic 
purpose, presently more than 50% are being done for staging versus 15% for diagnosing the 
parenchymal liver disease5. In addition, biopsies are often done to help in guiding the 
management of hepatitis C and nonalcoholic steatohepatitis and to assess the response to 
therapy2, 3. The increased use of liver transplantation as standard treatment of end stage 
liver disease of diverse etiologies has led to more biopsies being performed to differentiate 
the cause of graft dysfunction and to assess the suitability of potential liver donors for 
transplantation1-3. The dramatic increase in obesity, diabetes, hyperlipidaemia and 
hypertension (the metabolic syndrome) in western societies and its accompanying fatty liver 
problems are requiring liver biopsy for histological assessment2. Evaluation of liver 
histology remains very important as LB is reported to change the clinical diagnosis in 8-14%, 
management in 12-18% and frequency of liver test monitoring in 36% of cases5. Hence the 
main indication are a) chronic hepatitis- for grading, staging, establishing a therapeutic 
strategy and monitoring therapy, b)unexplained abnormal liver function tests or 
hepatomegaly and c) follow up of patients after liver transplantation. However no liver 
biopsy is free of risk as it is an invasive procedure. Rational assessment of overall risk in LB 
however is hampered by the wide variation in the indication and its outcome reported in 
the existing literature.  
2. Factors that may influence the risk of complication following liver biopsy 
Several factors my influence the risk of complication following liver biopsy and are listed in 
table 1 
Uncooperative patient- The risk of bleeding is enhanced in an uncooperative patient who may 
inadvertently move when the biopsy needle is in the liver leading to tear or laceration1-4. In 
such uncooperative patients if liver biopsy was required it could be achieved by performing 
the procedure under moderate or deep sedation or under general anaesthesia6, 7. A 
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transjugular approach is an alternative option8. Conscious sedation for LB are performed 
using midazolam and fentanyl or mepverdine6,7. This adds to small risk and the cost of 
conscious sedation to the procedure. However patients are found to be remarkably 
cooperative and usually breathe somewhat superficially and will hold their breath if 
instructed6,7. However while sedation may allay anxiety and pain there is no strong 
evidence to suggest that it either increases or reduces the risk of major complications. It 
however makes an uncooperative patient cooperative1. 
 
Factors that may influence the risk of complication following liver biopsy 
 Patient cooperation 
 Coagulation status / bleeding disorders 
 Operator experience 
 Advanced age 
 Certain pathologies (liver cirrhosis, amyloidosis, malignancy, renal failure) 
 Use of image guidance 
 ascites 
 Type of technique (percutaneous / transvenous) 
 Number of needle passes 
 Needle diameter (large needle) 
 Type of needle (cutting or Automatic) 
 Blind technique 
Table 1. 
Ascites-_Moderate to severe ascites_is likely to make it difficult to hit the liver via the 
standard intercostal approach. In such patients, options would include total therapeutic 
paracentesis performed immediately prior to palpation /percussion guided transcutaneous 
biopsy or transvenous or laparoscopic biopsy9.There are however reports of successful LB 
under CT scan or US guidance without increasing the risk of bleeding9. 
Mass lesion-  Although LB in patients with mass lesion is generally safe, biopsy of known 
vascular lesion should be avoided10. Similarly biopsy of potentially malignant lesion should 
be avoided because it is believed that tumour vessels are more likely to bleed. However 
with the use of ultrasound colour Doppler to guide the site of biopsy, large tumour vessels 
and liver vessels can be identified and avoided1,11,12. Biopsy of malignant lesion is also 
associated with a risk of tumour spread usually along the biopsy tract. The risk is estimated 
to be around 0 to 0.13%12 and the risk decreases with use of co-axial approach (i.e. utilization 
of a 17 gauze introducer and 18 gauze biopsy needle introduced along a co-axial plane13. 
Impaired haemostasis- Standard percutaneous liver biopsy is often withheld in patients with a 
PT-INR above 1.51-4. However while alteration in haematological parameters are of utmost 
importance when considering the risk associated with liver biopsy, strict cutoffs for PT-INR 
may not be prudent in light of the risk associated with plasma infusion1-4. While it is often 
presumed that abnormal increase in the PT-INR correlates with an increased risk of bleeding 
and that correcting the abnormal PT-INR with plasma replacement therapy or agents such 
as recombinant activated factor V11 will reduce or eliminate the risk of bleeding, the 
available data in the literature are not sufficient to support this presumption particularly in 
mild coagulopathy defined as INR of less than 2.014-15. Hence it is not clear whether 
prolongation of the INR in chronic liver disease while of prognostic significance actually 
represents a net diathesis or not2. Thus better tests are needed to more acutely define the net 
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bleeding risks in these patients. A new measure of coagulation in liver disease has recently 
been introduced, the INRLiver16,17 . It recalculates the international sensitivity index from a 
reference point of patients with liver disease rather than Coumadin –treated patients as has 
been the convention16.17. Whether this test will provide a reliable measure of bleeding risk 
remains to be determined. Therefore a large randomized controlled trial of plasma 
replacement therapy in patients undergoing invasive therapy appears to be warranted1. 
There are however several conditions which are more definitely associated with enhanced 
risk of bleeding and therefore warrant additional caution. These include patients with factor 
V11 (FV11) or 1X (F1X) deficiency, von Willebrand’s disease, other hereditary bleeding 
disorders and those with sickle cell anaemia17. Patients with known underlying 
coagulopathy requiring liver biopsy represents a challenge but liver biopsy can be 
performed in these patients with definitive factor replacement. Nonetheless the risk benefit 
ratio must be carefully considered on a case by case basis 
2.1 Ultrasound guided LB 
This has been done to reduce the risk of both minor and major complications by avoiding 
large intra-hepatic vessels and other structures in the vicinity (gall bladder, colon, lung) and 
by decreasing the passes to sample a good specimen18-21. Ultrasound (US) may influence in 
selecting the site of puncture as was noted in 15% of cases in one study19. The main causes 
for the change in site were due to ascites or small liver. US guided liver biopsy is reported to 
be performed in 56% of cases in France and in 76% of cases in USA20,21. This could either be 
performed as US guided or US assisted LB. US guided LB is particularly reserved for small 
liver, interposition of colon or lung, focal liver lesion (Haemangioma or cysts) or in patients 
with increased risk of bleeding19-21.  
3. Post biopsy care and complications 
Rate of complications vary in different case series and relate in part to operator experience 
although the most experienced clinician still will encounter complications1-4. The risk of 
major complications is listed in table 2. Intraoperative needle biopsy observation indicates 
that almost all patients have transient bleeding from the capsular puncture site1,2. Following 
outpatient LB the period of observation varies among different institution but usually does 
not exceed 6 hours1-4. Patients who have had uneventful single pass biopsy may be 
discharged after 3 hours observation and if patients require analgesia may need observation 
for at least 4 hours2-4. The majority of major complications requiring hospitalization have 
been shown in prospective observational series to occur within 3 hours of biopsy, although 
later complication can occasionally ensue1-4. 
3.1 Complications 
Pain- Pain is the most common complication of percutaneous liver biopsy and is seen in up 
to 84% of patients including those with mild discomfort22. Often pain can be managed with 
small amounts of narcotics typically codeine1-4. The pain immediately after the procedure at 
times can be very distressing and some patients remember the procedure as a very 
unpleasant experience. Moderate to severe pain however is seen in 1-5% of the patients and 
should raise the possibility of a complication such as active bleeding or trauma to adjacent 
structures like gall bladder23. The mechanism of pain following percutaneous biopsy is most 
likely a result of bleeding or perhaps bile extravasation from the liver puncture wound with 
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subsequent capsular swelling although the exact mechanism for the pain remains uncertain 
in most cases2-4. The site of biopsy (intercostal or subcostal) did not influence the incidence 
of pain24. However the use of US guidance, premedication with midazolam and fenatnyl 
and self delivering of mixture of N2o and oxygen via mask decreased significantly the 
incidence of post biopsy pain and anxiety24,25. For LB performed with US guidance the 
incidence of pain decreased from 47% to 35%. The 2 factors that were demonstrated to be 
associated with increased use of post procedure analgesics are, cutting biopsy needles and 
less experienced operator25,26. Other controversial factors associated with more pain are 
larger needle, increasing number of biopsy passes, hepatitis C infection, younger age and 
history of intravenous drug abuse27. The use of automatic cutting needles are associated 
with a low incidence of postbiopsy pain with a reported incidence 31.4 to 34.3% in 
comparison to hand held needles( 40.6 to 52.6%)25,26.Besides the above factors the patient 
characteristics play an important role in pain medication requirement after LB . Thus 
previous intravenous drug abusers and those with significant anxiety prior to LB are 
associated with 9 and 4 fold increase in post biopsy analgesia respectively27. 
 
Scenario Reported frequency (%) 
Pain at biopsy site or right shoulder 
(pleuritic, peritonel, diaphragmatic) 
0.056-22 
Haemorrhage  
 -intraperitoneal 0.03-0.7 
 -intrahepatic or subcapsular  0.59 -0.23 
 -haemobilia 0.058-0.2 
Bile peritonitis 0.03-0.22 
Pneumothorax and /or pleural effusion 0.08-0.28 
Haemothorax 0.18-0.49 
Arteriovenous fistula  5.4 
Anaesthetic reaction  0.029 
Biopsy of adjacent organs 0.001-0.044 
lung -0.001- 0.014 
gall bladder -0.034- 0.117 
kidney -0.029- 0.096 
colon  -0.0038- 0.0044 
Reaction to anaesthetic agent  0.029 
Breakage of needle 0.02- 0.059 
Death 0.0083-0.03 
Table 2. Potential complications and the range in reported frequencies 
A decision about when to investigate with imaging and or to hospitalize the patient for 
observation due to pain should be made on a case by case basis1-4. When pain is severe 
enough to require hospitalization radiological evaluation is usually warranted. While some 
would prefer the use of ultrasound as an initial investigation due to the ease with which it 
can be performed , others would perform an abdominal CT with contrast to be more 
definitive1-4(figure 1). 
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Fig. 1. CT scan revealing intraperitoneal bleeding following subcostal percutaneous liver 
biopsy. The bleeding was successfully managed conservatively 
Bleeding- Bleeding could either be major or minor. The risk of major bleeding is reported to 
be around 0.16%1-4,28-30. Major bleeding is severe bleeding defined clinically by change in 
vital signs with radiographic evidence of intraperitoneal bleeding that requires 
hospitalization with the likelihood of transfusion or even radiologic intervention or surgery. 
Such bleeding has been estimated to occur in between 1 in 2500, to 1 in 10,000 biopsies after 
intercostal percutaneous approach for diffuse nonfocal liver disease23,31-33. Minor bleeding is 
less severe bleeding which is characterized by pain or reduced blood pressure or 
tachycardia but not requiring transfusion or intervention and occurs in approximately in 1 
in 500 biopsies. About 18 to 20% of intrahepatic and perihepatic bleeding is also detected on 
ultrasonography28. Severe bleeding is usually clinically evident within 2 to 4 hours but late 
haemorrhage can occur even up to one week after biopsy34. Premature clot dissolution due 
to liver disease associated with hyperfibrinolysis has been proposed to play a role in some 
patients especially those with delayed bleeding, although this has not been extensively 
studied35. Some degree of bleeding occur after all percutaneous liver biopsies based on 
observation made on laparoscopy. 
Bleeding can manifest as haemoperitoneum(0.3 to 0.7%), intrahepatic haematoma(0.59 to 
0.23%) or haemobilia(0.058- 0.2%) 28-30(figure 1). Bleeding into peritoneal cavity produces 
pain, hypotension or less frequently may be asymptomatic. Intrahepatic haemtoma occurs in 
1 to 23% of cases and are localized to intrahepatic or subcapsular region28,29. Usually they 
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are small and asymptomatic but larger haematomas may cause pain from stretching of the 
liver capsule, hypotension or a delayed decrease in haematocrit28,29. The incidence of 
haematoma after LB seems to be high after LB with larger needles30. Conservative treatment 
of haematoma together with a close follow up by US is generally sufficient1-2,36. The least 
common of the haemorrhagic complications is haemobilia which presents with the classical 
triad of upper gastrointestinal bleeding, pain and jaundice4,18,36. It may appear acutely 
following simultaneous perforation of adjacent intrahepatic bile ducts and blood vessels or 
more commonly much later following the erosion of haematoma or psuedoaneurysm into a 
bile duct37. This occurs typically 5 days following the biopsy31. Haemobilia is a very rare 
event with a frequency of 0.0006 to 0.023% in large series31,37,38. If bile is checked routinely 
after LB, haemobilia may be detected in 10% of cases31,37,38. Large volume of haemobilia may 
cause acute pancreatitis, although this is a very rare event with only 5 cases being reported 
in the literature39. 
The risk of bleeding is influenced by several factors including bleeding disorders, 
advanced age, ascites, high number of passages, large needle size, blind technique and 
certain liver pathologies including liver cirrhosis , amyloidosis, malignancy and renal 
failure1-4,28,31. The factors that are also related to the risk of bleeding include arterial 
bleeding and operator experience. Whether cutting needle(eg Trucut and automated 
variants) have a different risk than aspiration needles(eg, Menghini or Jamshidi) is 
unknown although some retrospective data suggest that cutting needle may be associated 
with slightly greater risk31. At particular risk for bleeding are patients with chronic renal 
failure, those with underlying coagulopathy due to congenital abnormalities in 
coagulation parameter (such as haemophilics) and those with cirrhosis who may have 
acquired abnormalities in coagulation parameter. Use of DDAVP immediately before liver 
biopsy (0.3ug/kg ) body weight in patients with renal failure undergoing invasive 
procedure is useful40,41. In patients on chronic renal replacement therapy, dialysis is often 
performed prior to liver biopsy1,2. Although platelet count less than 60,000/cmm, INR 
greater than 1.3 and bleeding time > 10 minutes are well known practical contraindication 
to percutaneous LB, bleeding from liver does not correlate with the indices of peripheral 
coagulation when these are mildly impaired thus making bleeding an unpredictable 
event42,43. The accurate prediction of bleeding based on coagulation indices is problematic 
as the available data suggest poor relationship between bleeding and common laboratory 
tests (such as platelets, PT-NR etc)42,43. As a result there is wide variation in “acceptable” 
prebiopsy coagulation parameter44. Whether the use of prophylactic blood products alters 
the risk of bleeding is currently unknown1-3. Furthermore because of the conventional 
parameter of coagulation correlate poorly with risk of bleeding, recommendation 
regarding correction of coagulation indices is limited and tempered by the risk of blood 
product exposure42,43. 
Transvenous liver biopsy (typically with jugular approach) is often recommended in 
patients with known or suspected bleeding diathesis because it is commonly perceived to be 
safer8. However a recent systematic review reported minor and major complication in 6.5% 
and 0.6% respectively among the 7649 patients who underwent transvenous biopsy and 
may be related to capsular piercing with subsequent haemorrhage32. However as this study 
was retrospective, there may have been a selective bias (i.e. it is highly likely that patients 
suspected to be at risk of bleeding would have been preferred for transvenous rather than 
percutaneous biopsy).  
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3.2 Miscellaneous 
A number of other complications have been reported after liver biopsy. These include 
pneumothorax, hemothorax, perforation of any of the several viscous organs, bile 
peritonitis, infection (bacteraemia. abscess, sepsis), haemobilia, intrahepatic arteriovenous 
fistula, neuralgia and rare complication such ventricular arrhythmias with transvenous 
biopsy1-4. 
3.2.1 Infective complications 
Transient bacteraemia which has been reported in 5.8 to 13.5% of patients after LB, is in 
most cases harmless31. Intrahepatic abscess, septicaemia and septic shock are much rare 
events occurring only in patients with biliary obstruction and cholangitis or when the colon 
is incidentally punctured18. Infectious complication appear to be increased in post transplant 
patients who underwent choledochojejunostomy during liver transplantation45. There is 
however no recommendations of prophylactic antibiotics in patients scheduled for LB 
except in those with valvular heart disease 
3.2.2 Complications in the thorax 
Haemothorax, pneumothorax, leakage of ascites in the pleural cavity, subcutaneous 
emphysema occur after injury of pleura or lung or right diaphragm18,31,46. Haemothorax can 
occur even in US assisted LB when the patient changes his position or takes a deep 
inspiration after the site of puncture was set, the cause of bleeding being an injury to a 
diaphragmatic vessel46 . Pneumothorax is critical to recognize immediately after biopsy in 
presence of reduced breath sounds and typical radiographic findings because it can lead to 
immediate catastrophic outcome if not promptly recognized and treated18,31. 
3.2.3 Puncture of other viscera 
This occurs rarely (0.01 to0.1%) and involves usually gall bladder, colon, and right kidney. 
The incidence is significantly reduced when LB is performed under US guidance49,48 . Bile 
peritonitis , formation of bilioma or bilious pleural effusion occur mainly in patients with 
biliary obstruction although they are reports of them occurring even in patients without 
biliary obstruction or when the gall bladder is incidentally punctured48,49.  
Other very rare complications include reaction to the anaesthetic agents, breakage of the 
needle and arterioportal fistula, neuralgia and ventricular arrythmias 42,45. 
Death- Is very uncommon after percutaneous biopsy but precise figure vary widely in the 
literature ranging from 0.009% to 0.11% .and is usually related to haemorrhage10,20,24,31,41,45,49. 
Mortality after transvenous biopsies was 0.0009% (9 in 10,000) in a recent report of 7649 
transvenous biopsies but again may reflect the selection of higher risk patients for this 
intervention40. The main cause of death after LB is intraperitoneal bleeding mainly occurring 
in patients with malignancy or cirrhosis45. The incidence of fatal complications can be 
significantly reduced by careful post biopsy observation with prompt recognition of 
bleeding and aggressive subsequent therapy which may involve transfusion followed by 
therapeutic embolisation or laparotomy18 
3.3 Management 
The most critical aspect of management of complications such as bleeding, pneumothorax 
and visceral perforation is to recognize that one these complications has occurred. 
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Suspicion of a potential complication should be high when the patient complains of pain 
that is out of proportion to the clinical events that surrounded the biopsy and is 
associated with drop in blood pressure and tachycardia and is then confirmed by 
radiological investigation. All complications are supported by initial resuscitation. 
Bleeding is most often managed expectantly with placement of wide bore intravenous 
cannula, volume resuscitation and blood transfusion as necessary. Angiographic 
embolisation and surgery may be required in some of these patients with persistent 
bleeding. Pneumothorax may be self limiting but may require more aggressive 
intervention depending on the severity of symptoms. Visceral perforation is usually 
managed expectantly in most situations. Observation is all that may be required although 
occasionally surgical intervention may be needed in the case of gall bladder puncture 
with persistent bile leak or in case of secondary peritonitis 
4. Recommendations 
1. The person who performs the LB should be acutely aware of the multiple potential 
complications (including death) that may occur after liver biopsy and it is of outmost 
importance to discuss these appropriately with the patient’s beforehand (class 1. Level 
C evidence) 
2. Percutaneous liver biopsy with or without image guidance is appropriate only in 
cooperative patients and this technique should not be utilized in uncooperative 
patients(claas 1 level C) 
3. Uncooperative patients who require liver biopsy should undergo the procedure under 
general anaesthesia or via transvenous route(class 1 level C) 
4. In patients with clinically evident ascites requiring a liver biopsy a transvenous 
approach is generally recommended although percutaneous biopsy (after removal of 
ascites) or laparoscopic biopsy are acceptable alternatives(class 1 level C) 
5. Haematological abnormalities particularly low platelet count (levels less than 50,000-
60,000/ml) should be dealt with platelet transfusion prior to the procedure. This applies 
for both percutaneous and transvenous approach 
6. The use of prophylactic or rescue strategies such as plasma, fibrinolytic inhibitors or 
recombinant factors should be considered in specific situations although their 
effectiveness remains to be established.(class 11a, level C) 
7. In patients with renal failure or on hemodialysis , desmopressin(DDAVP) may be 
considered, although its use is necessary in patients on stable dialysis regimen(class 11a, 
level B) 
8. Patients on chronic haemodialysis should be well dialysed prior to liver biopsy and 
heparin should be avoided if at all possible(class 1, level C) 
5. Conclusion 
The indications for liver biopsy are evolving. While liver biopsy may play a major role in 
management of some of the hepatic disorders, it is not without risk. Mild pain following the 
procedure is not uncommon however persistent and severe pain should warrant further 
investigation to rule out significant intraperitoneal bleed. Liver biopsy performed under 
ultrasound guidance and premedication is reported to significantly reduce complications 
including pain. The risk of major bleeding post liver biopsy is low but is of serious 
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consequence as it is the main cause of a rare event of death. Among the various factors that 
may influence complication risk, patients coagulation status and operator experience are of 
outmost importance. The coagulation status should be optimized to the extent possible with 
platelet and coagulation factor infusion and the use of DDAVP and haemodialysis in 
patients with renal failure. The most critical aspect of management of these complications is 
to be acutely aware of it and to promptly treat it. 
6. References 
[1] Ghent CN. Percutaneous liver biopsy : Reflections and refinements . Can J Gastroenterol. 
2006;20(2):75-9 
[2] Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. 
Hepatology. 2009;49(3):1017-1044 
[3] Siegel CA, Silas AW, Suriawinata AA, van Leeuwen DJ. Liver biopsy 2005: When and 
how ? Cleve Clin J Med.2005;72(3):199-224 
[4] Friedman LS. Controversies in liver biopsy: who, where, when, how, why?. Curr 
Gastroenterol Rep.2004;6(1):30-36 
[5] Sheela H, Seela S, Caldwell C, Boyer JL, Jain D. Liver biopsy: evolving role in the new 
millennium. J Clin Gastroenterol.2005;39:603-10 
[6] Alexander GA, smith BJ, Midazolam sedation for percutaneous liver biopsy. Dig Dis Sci. 
1993;38(12):2209-2211 
[7] Cartera I, Negre I, Samii K, Buffer C. Patient administration nitrous oxide/ oxygen 
inhalation provides safe and effective analgesics for percutaneous liver biopsy: a 
randomized placebo 
[8] Lebrec D, Goldfar G, Degott C, Rueff B, Benhamou JP. Transvenous liver biopsy :an 
experience based on 1000 hepatic tissue sampling with this procedure. 
Gastroenterology. 1982;83:338-40 
[9] Little AF, Ferris JV, Dodd GD 3rd, Baron RL. Image- guided percutaneous hepatic biopsy: 
effect of ascites on the complication rate. Radiology.1996;199(1):79-83 
[10] McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21 year experience with major 
haemorrhage after percutaneous liver biopsy. Gastroenterology.1990;99(5):1396-
1400 
[11] Chang S, Kim SH, Lim HK, Lee WJ, Choi D, Lim JH. Needle tract implantation after 
sonographically guided percutaneous biopsy of hepatocellular carcinoma: 
evaluation of doubling time, frequency and features on CT. AJR Am J 
Roentgenol.2005;185(2):400-5 
[12] Tung WC, Huang YJ, Leung SW, Kuo FY, Tung HD, Wang JH et al. Incidence of needle 
tract seeding and response of soft tissue metastasis by hepatocellular carcinoma 
post radiotherapy. Liver Int.2007;27(2):192-200 
[13] Maturen KE, Nghiem HV, Marrero JA, Hussain HK, Higgins EG, Fox GA et al. 
Lack of tumour seeding of hepatocellular carcinoma after percutaneous needle 
biopsy using co-axial cutting needle technique. AJR Am J 
Roentgenol.2006;187(5):1184-87 
www.intechopen.com
 
Liver Biopsy 
 
402 
[14] Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results 
predict bleeding in the setting of invasive procedures: an evidence based review. 
Transfusion.2005;45:1413-25 
[15] Stanworth SJ, Brunskill SJ, Hyde CJ, McClelland DB, Murphy MF. Is fresh frozen 
plasma clinically effective? A systematic review of randomized controlled trials. Br 
J Haematol.2004;126(1):139-52 
[16] Bellest L, Eschwege V, Poupon R, Chazouilleres O, Robert A. A modified international 
normalized ratio as an effective way of prothrombin time standardization in 
hepatology. Hepatology .2007;46(2):528-34 
[17] Theodore D, Fried MW, Kleiner DE, Kroner BL, Goedert JJ, Eyster ME et al. Liver 
biopsy in patients with inherited disorders of coagulation and chronic hepatitis C. 
Haemophilia.2004;10(5):413-21 
[18] Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. 
Gut.1999.45(suppl 1V):1V1- 1V11 
[19] Cadranel JF, Rufat P, Degos F. practices of liver biopsy in France. Results of a 
prospective nationwide survey. For the group of epidemiology of the French 
association for the study of liver. Hepatology.2000;32:477-81 
[20] Riley TR 3rd. How often does ultrasound marking change the liver biopsy site ? Am J 
Gastroenetrol. 1999;94(11):3320-22 
[21] Angtuaco TL, Lal SK, Banaad-Omiotek GD, Zaidi SS, Howden CW. Current liver 
biopsy practices for suspected parenchymal liver diseases in the united states: the 
evolving role of radiologists. Am J Gastroenetrol.2002;97(6):1468-71 
[22] Eisenberg E, Konopniki M, Veitsman E, Kramskay R, Gaintini D, Baruch Y. Prevalence 
and characteristics of pain induced by percutaneous liver biopsy. Anaesth 
Analg.2003;96(5):1392-96 
[23] Janes CH, Lindor KD. Outcome of patients hospitalized for complications after 
outpatient liver biopsy. Ann intern Med.1993;118(2):96-98 
[24] Tan KT, Rajan DK, Kachura JR, Hayeems E, Simons ME, Ho CS. Pain after 
percutaneous liver biopsy for diffuse hepatic disease: a randomized trial 
comparing subcostal and intercostal approaches. J Vas Interv 
Radiol.2005;16(9):1215-19 
[25] Lindor KD, Bru C, Jorgensen RA , Rakela J, Bordas JM, Gross JB et al. The role of 
ultrasonography and automatic needle biopsy in outpatient percutaneous liver 
biopsy. Hepatology.1996;23(5):1079-83 
[26] Chevallier P, Ruitor TF, Denys A et al. Significance of operator experience in diagnostic 
accuracy of biopsy gun procedures. Eur Radiol.1994;4:430-33 
[27] Riley TR 3rd. Predictors of pain medication use after percutaneous liver biopsy. Dig Dis 
Sci.2002;47(10):2151-53 
[28] Minuk GY, Sutherland LR, Wiseman DA, MacDonald FR, Ding DL. Prospective study 
of the incidence of ultrasound detected intrahepatic and subcapsular haematoma in 
patients randomized to 6 or 24 hours of bed rest after percutaneous liver biopsy. 
Gastroenetrology.1987;92(2):290-93 
www.intechopen.com
 
Complications of Liver Biopsy - Risk Factors, Management and Recommendations 
 
403 
[29] Lankisch PG, Thiele E, Mahlke R, Lubbers H. Riesner K. Prospective study of the 
incidence of ultrasound detected hepatic haematomas 2 to 24 hours after 
percutaneous liver biopsy. Z Gastroenterol.1990;28(5):247-50 
[30] Sugano S, Sumino Y, Hatori T, Mizugami H, Kuwafuni T, Abei T. incidence of 
ultrasound detected intrahepatic haematoma due to trucut needle liver biopsy. Dig 
Dis Sci.1991;36(9):1229-33 
[31] Piccinino F, Sagnelli E, Pasquale G, Giusti G. complications following percutaneous 
liver biopsy. A multicentre retrospective study on 68,276 biopsies . J 
Hepatol.1986;2(1):165-73 
[32] Kalambokis G, Manousou P, Vibhakron S, Marelli I, Cholongetas E, Senzolo M et al. 
Transjugualr liver biopsy: indications , adequacy , quality of specimen and 
complications. a systematic review . J Hepatol.2007;47:284-94 
[33] Perrault J, McGill DB, Ott BJ, Taylor WF. Liver biopsy complications in 1000 inpatients 
and outpatients. Gastroenetrology.1978;74:103-106 
[34] Reicher CM, Weisenthal LM, Kleen HG. Delayed haemorrhage after percutaneous liver 
biopsy. J Clin Gastroenterol. 1983;5:263-66 
[35] Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR. 
Coagulopathies disorders and hemostasis in liver disease pathophysiology and 
critical assessment of current management . Hepatology.2006;44:1039-1046 
[36] Bravo AA, Sheth SG, Chopra S. liver biopsy . N Engl J Med.2001;344(7):495-500 
[37] Hodgson RS, Taylor- Robinson SD, Jackson JE. Haematochezia in Crohn’s disease 
caused by late onset haemobilia following percutaneous liver biopsy . Eur J 
Gastroenterol Hepatol.2004;16(2):229-32 
[38] Lin CL, Chang JJ, Lee TS, Lui KW, Yen CL. Gall bladder polyp as a manifestation of 
haemobilia caused by arterial portal fistula after percutaneous liver biopsy: a case 
report. World J Gastroenterol.2005;14:11(2):305-307 
[39] Machicao VI, Lukens FJ, Lange SM, Scolapio JS. Arterioportal fistula causing acute 
pancreatitis and haemobilia after liver biopsy. J Clin Gastroenetrol.2002;34(4):481-
84 
[40] Mannucci PM, Remuzzi G, Pusineri F, Lombordi R, Valsecchi C, Mecca G et al. 
Deamino-8-D-arginine vasopressin shortens the bleeding time in uraemia. N Engl J 
Med. 1983;308(1):8-12 
[41] DiMichele DM, Hathaway WE. Use of DDAVP in inherited and acquired platelet 
dysfunction. Am J Haematol. 1990;33(1):39-45 
[42] McVay PA, Toy PT. lack of increased bleeding after liver biopsy in patients with mild 
hemostatic abnormalities. Am J Clin Pathol.1990;94(6):747-53 
[43] Dillon JF, Simpson KJ, Hayes PC. Liver biliary bleeding time: an unpredictable event. J 
Gastroenterol Hepatol.1994;9(3):269-71 
[44] Sue M, Caldwell SH, Dickson RC, Macalindong C, Rourk RM, Charles C et al. 
Variations between centers in technique and guidelines for liver biopsy. Liver 
1996;16(4):267-70 
[45] Bubak ME, Porayko MK, Krom RA, Wiesner RH, Complications of liver biopsy in liver 
transplant patients: increased sepsis associated with choledochojejunostomy. 
Hepatology.1991:14(6);1063-1065 
www.intechopen.com
 
Liver Biopsy 
 
404 
[46] Myers RP, Fong A, Shaheen AA. Utilization rates, complications and costs of 
percutaneous liver biopsy ; a population based study including 4275 biopsies . liver 
Int.2008;28(5):705-12 
[47] Chahal PS, Ready J. Haemothorax after percutaneous liver biopsy: an unusual 
complications. Am J Gastroentrol.2002;97:1068-9 
[48] Ahluwalia JP, LaBrecque DR. A large bilioma causing gastric outlet obstruction after a 
percutaneous liver biopsy. J Clin Gastroenterol.2004;38(6):535-39 
[49] Lublin M, Danforth DN. Iatrogenic gall bladder perforation: conservative management 
by percutaneous drainage and cholecystectomy. Am Surg.2001;67(8):760-63 
www.intechopen.com
Liver Biopsy
Edited by Dr Hirokazu Takahashi
ISBN 978-953-307-644-7
Hard cover, 404 pages
Publisher InTech
Published online 06, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Liver biopsy is recommended as the gold standard method to determine diagnosis, fibrosis staging, prognosis
and therapeutic indications in patients with chronic liver disease. However, liver biopsy is an invasive
procedure with a risk of complications which can be serious. This book provides the management of the
complications in liver biopsy. Additionally, this book provides also the references for the new technology of liver
biopsy including the non-invasive elastography, imaging methods and blood panels which could be the
alternatives to liver biopsy. The non-invasive methods, especially the elastography, which is the new
procedure in hot topics, which were frequently reported in these years. In this book, the professionals of
elastography show the mechanism, availability and how to use this technology in a clinical field of
elastography. The comprehension of elastography could be a great help for better dealing and for
understanding of liver biopsy.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Norman Oneil Machado (2011). Complications of Liver Biopsy - Risk Factors, Management and
Recommendations, Liver Biopsy, Dr Hirokazu Takahashi (Ed.), ISBN: 978-953-307-644-7, InTech, Available
from: http://www.intechopen.com/books/liver-biopsy/complications-of-liver-biopsy-risk-factors-management-
and-recommendations
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
